BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahenkorah S, Cassells I, Deroose CM, Cardinaels T, Burgoyne AR, Bormans G, Ooms M, Cleeren F. Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside. Pharmaceutics 2021;13:599. [PMID: 33919391 DOI: 10.3390/pharmaceutics13050599] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Nasr D, Kumar PA, Zerdan MB, Ghelani G, Dutta D, Graziano S, Lim SH. Radioimmunoconjugates in the age of modern immuno-oncology. Life Sciences 2022;310:121126. [DOI: 10.1016/j.lfs.2022.121126] [Reference Citation Analysis]
2 Castillo Seoane D, De Saint-hubert M, Ahenkorah S, Saldarriaga Vargas C, Ooms M, Struelens L, Koole M. Gamma counting protocols for the accurate quantification of 225Ac and 213Bi without the need for a secular equilibrium between parent and gamma-emitting daughter. EJNMMI radiopharm chem 2022;7. [DOI: 10.1186/s41181-022-00174-z] [Reference Citation Analysis]
3 O’donoghue J, Zanzonico P, Humm J, Kesner A. Dosimetry in Radiopharmaceutical Therapy. J Nucl Med 2022;63:1467-1474. [DOI: 10.2967/jnumed.121.262305] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Horváth D, Vágner A, Szikra D, Trencsényi G, Demitri N, Guidolin N, Maiocchi A, Ghiani S, Travagin F, Giovenzana GB, Baranyai Z. Boosting Bismuth(III) Complexation for Targeted α‐Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA**. Angew Chem Int Ed 2022. [DOI: 10.1002/anie.202207120] [Reference Citation Analysis]
5 Csige K, Szabó JP, Kálmán-Szabó I, Dénes NS, Szikra D, Képes Z, Opposits G, Méhes G, Kertész I, Fenyvesi F, Trencsényi G, Hajdu I. In vivo investigation of Gallium-68 and Bismuth-205/206 labeled beta cyclodextrin for targeted alpha therapy of prostaglandin E2 receptor-expressing tumors in mice. Int J Pharm 2022;625:122132. [PMID: 36028082 DOI: 10.1016/j.ijpharm.2022.122132] [Reference Citation Analysis]
6 Ahenkorah S, Murce E, Cawthorne C, Ketchemen JP, Deroose CM, Cardinaels T, Seimbille Y, Fonge H, Gsell W, Bormans G, Ooms M, Cleeren F. 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals. Theranostics 2022;12:5971-85. [PMID: 35966589 DOI: 10.7150/thno.75336] [Reference Citation Analysis]
7 Salih S, Alkatheeri A, Alomaim W, Elliyanti A. Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges. Molecules 2022;27:5231. [DOI: 10.3390/molecules27165231] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Alsadi R, Djekidel M, Bouhali O, Doherty JO. Towards Routine Clinical Use of Dosimetry in [177Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives. Front Phys 2022;10:940677. [DOI: 10.3389/fphy.2022.940677] [Reference Citation Analysis]
9 Ingham A, Wharton L, El Sayed T, Southcott L, McNeil BL, Ezhova MB, Patrick BO, Jaraquemada-Peláez MG, Orvig C. H2ampa─Versatile Chelator for [203Pb]Pb2+, [213Bi]Bi3+, and [225Ac]Ac3. Inorg Chem 2022;61:9119-37. [PMID: 35678752 DOI: 10.1021/acs.inorgchem.2c00636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Franchi S, Di Marco V, Tosato M. Bismuth chelation for targeted alpha therapy: Current state of the art. Nucl Med Biol 2022:S0969-8051(22)02061-3. [PMID: 35753940 DOI: 10.1016/j.nucmedbio.2022.06.002] [Reference Citation Analysis]
11 Vasiliev AN, Ermolaev S, Lapshina EV, Bravo MG, Skasyrskaya AK. Production of 230 Pa as a Source for Medical Radionuclides 230 U and 226 Th Including Isolation by Liquid–liquid Extraction. Solvent Extraction and Ion Exchange. [DOI: 10.1080/07366299.2022.2088059] [Reference Citation Analysis]
12 Parrilha GL, dos Santos RG, Beraldo H. Applications of radiocomplexes with thiosemicarbazones and bis(thiosemicarbazones) in diagnostic and therapeutic nuclear medicine. Coordination Chemistry Reviews 2022;458:214418. [DOI: 10.1016/j.ccr.2022.214418] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
13 Cusnir R, Froidevaux P, Carbonez P, Straub M. Solid-phase extraction of 225Ac using ion-imprinted resin and 243Am as a radioactive tracer for internal dosimetry and incorporation measurements. Analytica Chimica Acta 2022;1194:339421. [DOI: 10.1016/j.aca.2021.339421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wagstaff P, Gabiña PM, Mínguez R, Roeske JC. Alpha particle microdosimetry calculations using a shallow neural network. Phys Med Biol 2022;67:025008. [DOI: 10.1088/1361-6560/ac499c] [Reference Citation Analysis]
15 Hu A, Brown V, MacMillan SN, Radchenko V, Yang H, Wharton L, Ramogida CF, Wilson JJ. Chelating the Alpha Therapy Radionuclides 225Ac3+ and 213Bi3+ with 18-Membered Macrocyclic Ligands Macrodipa and Py-Macrodipa. Inorg Chem 2021. [PMID: 34965102 DOI: 10.1021/acs.inorgchem.1c03670] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
16 Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, Van Cutsem E, Verslype C, Deroose CM. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. Cancers (Basel) 2021;14:129. [PMID: 35008293 DOI: 10.3390/cancers14010129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
17 El Fakiri M, Geis NM, Ayada N, Eder M, Eder AC. PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives. Cancers (Basel) 2021;13:3967. [PMID: 34439121 DOI: 10.3390/cancers13163967] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
18 Ermolaev S, Skasyrskaya A, Vasiliev A. A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling. Pharmaceutics 2021;13:914. [PMID: 34205580 DOI: 10.3390/pharmaceutics13060914] [Reference Citation Analysis]